Нетилмицин | КМАХ

Нетилмицин

Клиническая Микробиология и Антимикробная Химиотерапия. 2007; 9(3):253-267

​ Решедько Г.К.
аминогликозиды нетилмицин антибиотикорезистентность фармакодинамика обзор
Раздел
Антимикробные препараты
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2007; 9(3):253-267

Аннотация

Несмотря на появление новых классов антибактериальных препаратов, аминогликозидные антибиотики по-прежнему широко используются в клинической практике. Бактерицидное действие в отношении многих микроорганизмов, синергизм при сочетании с другими антибиотиками позволяют использовать этот класс антибактериальных препаратов для лечения нозокомиальных, в том числе тяжёлых, а также некоторых внебольничных инфекций. В данной статье представлен обзор данных по одному из наиболее интересных представителей аминогликозидов — нетилмицину. Подробно рассмотрены основные аспекты фармакокинетики, фармакодинамики и особенности клинического применения в сравнении с другими антимикробными препаратами. Большое внимание уделено обсуждению проблем антибиотикорезстентности к различным аминогликозидам в России и других странах.

  • 1. Cho J., Hamasaki K., Rando R.R. The binding site of a specific aminoglycoside binding RNA molecule. Biochemistry 1998; 37:4985-92.
  • 2. Wallis M.G., Schroeder R. The binding of antibiotics to RNA. Prog Biophys Mol Biol 1997; 67:141-54.
  • 3. Bryan L.E. Mechanisms of action of aminoglycoside antibiotics. In: Contemporary issues in infectious diseases. Root R.K., Sande M.A., eds. New York: Churchill Livingstone 1984; 1:17-36.
  • 4. Taber H.W., Muller J.P., Arrow A.S. Bacterial uptake of aminoglycoside antibiotics. Microbiol Rev 1987; 51:439-57.
  • 5. Hermann T., Westhoff E. Aminoglycoside binding to the hammerhead ribozyme: a general model for the interaction of cationic antibiotics with RNA. J Mol Biol 1998; 276:903-12.
  • 6. Jackson G.E., Lolans V.T., Daikos G.L. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990; 162:408-13.
  • 7. Reller L.B., Schoenknecht F.D., Kenny M.A., et al. Antibiotic susceptibility testing of Pseudomonas aeruginosa: selection of a control strain and criteria for magnesium and calcium content in media. Antimicrob Agents Chemother 1987; 31:1514-8.
  • 8. Damper P.D., Epstein W. Role of the membrane potencial in bacterial resistance to aminoglycoside antibiotics. Antimicrob Agents Chemother 1981; 20:803-8.
  • 9. Harrell L.R., Evans L.B. Anaerobic resistance of clinical isolates of Staphylococcus aureus to aminoglycosides. Antimicrob Agents Chemother 1978; 14:927-9.
  • 10. Bryan L.E., Kowand S.K., Van Den Elzen H.M. Mechanism of aminoglycoside antibiotic resistance in anaerobic bacteria. Clostridium perfringens and Bacteroides fragilis. Antimicrob Agents Chemother 1979; 15:7-13.
  • 11. Kantor R.J., Norden C.W. In vitro activity of netilmicin, gentamicin and amikacin. Antimicrob Agents Chemother 1977; 11:126-31.
  • 12. Meyers B.R., Hirschman S.Z. Antimicrobial activity in vitro of netilmicin and comparison with sisomicin, gentamicin, and tobramicin. Antimicrob Agents Chemother 1977; 11:118-21.
  • 13. Rahal J.J., Simberkoff M.S., Kagan K., et. al. Bactericidal efficacy of Sch 20569 and amikacin against gentamicinsensitive and –resistant organisms. Antimicrob Agents Chemother 1976; 9:595-99.
  • 14. Phillips I., Shannon K.P.. Aminoglycosides and aminocyclitols. In: Antibiotic and Chemotherapy. O'Grady F.O., Lambert H.P., Finch R.G., Greenwood D., eds.; 2003.
  • 15. Naber KG, Grimm H, Rosenthal EJ, et. al. Resistance to aminoglycosides: the situation in the Federal Republic of Germany. J Int Med Res 1990; 18 Suppl 4:6D-26D.
  • 16. Gospodarek E. Susceptibility to antibiotics and biochemical activity of strains Acinetobacter spp., isolated from various sources. Med Dosw Microbiol 1993; 45:331-7.
  • 17. Nemec A, Maixnerová M. Aminoglycoside resistance of Acinetobacter baumannii hospital strains in the Czech Republic. Klin Mikrobiol Infekc Lek 2004; 10:223-8.
  • 18. Hanberger H., Erlandsson M., Burman L.G., et. al. High antibiotic susceptibility among bacterial pathogens in Swedish ICUs. Report from a nation-wide surveillance program using TA90 as a novel index of susceptibility. Scand J Infect Dis 2004; 36:24-30.
  • 19. Mittermayer H., Rotter M., Breitfellner G., et. al Resistance of gram-negative bacilli and staphylococci from blood cultures to aminoglycoside antibiotics. Comparison of 3 in vitro investigations from Austria 1982-1988. Zentralbl Bakteriol 1990; 272:448-57.
  • 20. Quentin C., Grobost F., Fischer I., et. al. Antibiotic resistance of Staphylococcus aureus in urban experience: 6 month study in Aquitaine. Pathol Biol 2001; 49:33- 40.
  • 21. Stratchounski L.S., Shevelev A.N., Korovina N.A., et al. Resistance of E.coli isolated from children with community-acquired urinary tract infections (CA_UTI) in Russia^ results of multicenter study ARMID. Proceeding of 42nd Intersciience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 2002, San Diego, P.253, Abstr. G-1469.
  • 22. Сидоренко С.В., Резван С.П., Еремина Л.В. и др. Этиология тяжелых госпитальных инфекций в отделениях реанимации и антибиотикорезистентность среди их возбудителей. Антибиотики и химиотер 2005; 50:33-41.
  • 23. Розанова С.М., Руднов В.А., Перевалова Е.Ю. и др. Сравнительный анализ этиологии и антибиотикорезистентности основных возбудителей нозокомиальных инфекций в ОРИТ различного профиля города Екатеринбурга. Клиническая Микробиология и Антимикробная Химиотерапия 2005; 7:410-8.
  • 24. Isaksson B., Maller R., Nilsson L.E., et. al. Postantibiotic effect of aminoglycosides on staphylococci. J Antimicrob Chemother 1993; 32:215-22.
  • 25. Majtánová L, Majtán V. Postantibiotic effects of gentamicin and netilmicin on Serratia marcescens: effects on hydrophobicity and motility. Folia Microbiol 2000; 45:45-9.
  • 26. Bonfiglio G., Scuderi A.C., Russo G. Netilmicin: in vitro activity, time-kill evaluation and postantibiotic effect on microorganisms isolated from ocular infectious. Chemotherapy 2001; 47:117-22.
  • 27. Anding K., Krumme B., Pelz K., et.al. Pharmacokinetics and bactericidal activity of a single daily dose of netilmicin in the treatment of CAPD-associated peritonitis. Int J Clin Pharmacol Ther 1996; 34:465-9.
  • 28. Majtán V., Hostacká A. Influence of the postantibiotic effect and postantibiotic sub-MICs effect of netilmicin, tobramycin, ciprofloxacin and pefloxacin on alginate production by Pseudomonas aeruginosa. Folia Microbiol 1996; 41:228-32.
  • 29. Xiong Y.Q., Caillon J., Drugeon H., et. al. Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects. Antimicrob Agents Chemother 1996; 40:35-9.
  • 30. Rochon-Edouard S., Pestel-Caron M., Lemeland J.F., et. al. In vitro synergistic effects of double and triple combinations of beta-lactams, vancomicin, and netilmicin against meticillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2000; 44: 3055-60.
  • 31. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother 1990; 34:2387-91.
  • 32. Rahal J.J., Simberkoff M.S. Comparative bactericidal activity of penicillin-netilmicin and penicillin-gentamicin against enterococci. J Antimicrob Chemother 1986; 17:585-91.
  • 33. Chavanet P., Collin F., Muggeo E., et. al. The in vivo activity of co-amoxiclav with netilmicin against experimental methicillin and gentamicin resistant Staphylococcus epidermidis infection in rabbits. J Antimicrob Chemother 1993; 31:129-38.
  • 34. Francioli PB, Glauser MP. Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother 1993; 37:207-12.
  • 35. Duez J.M., Siebor E., Pechinot A., et. al. A. In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin. Pathol Biol 1995; 43:208-14.
  • 36. Arpi M. Time-kill studies and synergy testing of broadspectrum antibiotics against blood culture isolates. Chemotherapy 1988; 34:393-400.
  • 37. Baumgärtner M., Müller H.P., Wundt W. Antibiotic activity and synergism of ceftazidime and netilmicin against gram-negative pathogenic bacteria. Arzneimittelforschung 1983; 33:1615-9.
  • 38. Yamashiro Y., Ogake N., Takahata M., et. al. In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa. Jpn J Antibiot 2000; 53:194-200.
  • 39. Shaw K.J., Rather P.N., Hare R.S. et. al. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993; 57:138-63.
  • 40. Яковлев В.П. Нетилмицин. Антибиотики и химиотер 1993; 38:69-86.
  • 41. Ettlinger J.J., Bedford K.A., Lovering A.M., et. al. Pharmacokinetics of once-a-day netilmicin (6 mg/kg) in neonates.J Antimicrob Chemother 1996; 38:499-505.
  • 42. Tréluyer J.M., Merlé Y., Semlali A., et. al. Population pharmacokinetic analysis of netilmicin in neonates and infants with use of a nonparametric method. Clin Pharmacol Ther 2000; 67:600-9.
  • 43. Wagner B.P., Pfenninger J. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Intensive Care Med 1994; 20:365-7.
  • 44. Welling P.C., Baumueller A., Lau C.C. et al. Antimicrob Agents Chemother 1977; 12:328:34.
  • 45. Lanao J.M., Lopez A., Dominguez-Gil A., et. al. Distribution kinetics of netilmicin in human blister fluid: effect of renal impairment. Biopharm Drug Dispos 1991; 12:149-62.
  • 46. Martin C., Portet C., Bantz P., et. al. Pharmacokinetics and tissue penetration of single-dose netilmicin used for antibiotic prophylaxis during colo-rectal surgery. Pathol Biol 1990; 39:507-10.
  • 47. Hielte L., Malmborg A.S., Strandvick B. Serum and sputum concentrations of netilmicin in combination with acylureidopenicillin and cephalosporins in clinical treatment of pulmonary exacerbations in cystic fibrosis. J Antimicrob Chemother 1989; 23:885-90.
  • 48. Bruckner O., Trautmann M., Kolodziejczyk D., et. al. Netilmicin in human CSF after parenteral administration in patients with slightly and severely impaired blood CSF barrier. J Antimicrob Chemother 1983; 11:565-71.
  • 49. Kahlmeter G., Dahlager JI. Aminoglycoside toxicity – a review of clinical studies published between 1975 and 1982. JAC 1984; 13 Suppl. A: 9.
  • 50. Gorse G.J., Bernstein J.M., Cronin R.E., et. al. A comparison of netilmicin and tobramycin therapy in patients with renal impairment. Scand J Infect Dis 1992; 24:503- 14.
  • 51. Bhattacharya B.K., Gorringe H., Farr M.J. Netilmicin and nephrotoxicity. Lancet 1983 23; 2:216-7.
  • 52. Andronikou S., Giapros V.I., Cholevas V.I., et. al. Once daily dosing of netilmicin in neonatal and pediatric intensive care. Pediatr Nephrol 1996; 10:766-8.
  • 53. Giapros V.I., Andronikou S., Cholevas V.I., et. al. Renal function in premature infants during aminoglycoside therapy. Pediatr Nephrol 1995; 9:163-6.
  • 54. Santos M., Arevalo M., Colino C.I., et. al. Study on pharmacokinetics and nephrotoxicity of netilmicin in rabbits using a new dosage regimen. Methods Find Exp Clin Pharmacol 1997; 19:53-9.
  • 55. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother 1990; 34:2387-91.
  • 56. Blaser J., Simmen H.P., Thurnheer U., et. al. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995; 36:803-14.
  • 57. Van der Auwera P., Meunier F., Ibrahim S., et. al. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infection. Antimicrob Agents Chemother 1991; 35:640-7.
  • 58. Tulkens P.M. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991; 27, Suppl C:49-61.
  • 59. Vigano A., Principi N., Brivio L., et. al. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram trice daily for treatment gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992; 36:1499-503.
  • 60. Ferriols-Lisart R., Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141-50.
  • 61. Blaser J. Dosing aminoglycosides once a day. Schweiz Med Wochenschr Suppl 1996; 76:39S-48S.
  • 62. Laczika K., Staudinger T., Hollenstein U., et. al. Renal tolerability of four different once-daily dose regimen of netilmicin in critical care patients. Wien Klin Wochenschr 1997; 109:840-4.
  • 63. Gosden P.E., Bedford K.A., Dixon J.J., et. al. Pharma­cokinetics of once-a-day netilmicin (4.5 mg/kg) in neonates. J Chemother 2001; 13:270-6.
  • 64. Nayir A., Sirin A., Emre S., et. al. Pharmacokinetics of amikacin, netilmicin and tobramycin in children with chronic renal failure. Turk J Pediatr 1995; 37:111-6.
  • 65. Blaser J., Konig C., Simmen H.P., et. al. Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemother 1994; 33:341-8.
  • 66. Henning C., Medén-Britth G., Frölander F., et. al. Comparative study of netilmicin/tinidazole versus netilmicin/ clindamycin in the treatment of severe abdominal infections. Scand J Infect Dis 1984; 16:297-303.
  • 67. Bailey R.R., Lynn K.L., Robson R.A., et. al. Comparison of ciprofloxacin with netilmicin for the treatment of acute pyelonephritis. N Z Med J 1992; 105:102-3.
  • 68. Caramalli S., Amprimo M.C., Cavalli G., et. al. Effect and pharmacokinetics of netilmicin given as bolus intramuscular administration: an open comparative trial versus amikacin and fosfomycin in elderly patients affected by urinary tract infections. Int J Clin Pharmacol Res 1991; 11:55-65.
  • 69. Fridmond-Moller N., Maigaard S., Madsen P.O. Netilmicin treatment of complicated urinary tract infection in patients with renal function impairment. Antimicrob Agents Chemother 1979; 16:406-10.
  • 70. Francioli P., Ruch W., Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406-10.
  • 71. Sobliati M. The impact of novel dosing regimens on the safety and afficacy of aminoglycosides. Symp. in Sorento, Italy 1987:149-152.
  • 72. Laszlo D., Bacci S., Bosi A., et. al. Randomized trial comparing netilmicin plus imipenem-cilastatin versus netilmicin plus ceftazidime as empiric therapy for febrile neutropenic bone marrow transplant recipients. J Chemother 1997; 9:95-101.
  • 73. Studena M., Hlavacova E., Hel’pianska L., et al. Teicoplanin plus pefloxacine versus teicoplanin plus netilmicin in empiric therapy of febrile patients with cancer and neutropenia. A randomized study of two once daily regimens in patients with previously inserted catheters. Chemotherapy 1994; 40:431-4.
  • 74. Martin C., Portet C., Bantz P., et. al. Pharmacokinetics and tissue penetration of single-dose netilmicin used for antibiotic prophylaxis during colo-rectal surgery. Pathol Biol 1991; 39:507-10.
  • 75. Luzuriaga Graf J., Sanchez Chavez O., Arauz Arauz E. Antimicrobial prophylaxis in urologic surgery Arch Esp Urol 1990; 43:715-8.
  • 76. Scarpa R.M., Cossu F.M., Ambus G., et. al. Antibiotic prophylaxis with netilmicin in patients undergoing cystoscopic study. Minerva Urol Nefrol 1990; 42:167-71.
  • 77. McCormick P.A., Greenslade L., Kibbler C.C., et. al. A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients. Hepatology 1997; 25:833-6.
  • 78. Prins J.M., Buller H.R., Kuijper E.J., et. al. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections--a randomized clinical trial. J Antimicrob Chemother 1994; 33:823-35.
  • 79. Tange R.A., Dreschler W.A., Prins J.M., et. al. Ototoxicity and nephrotoxicity of gentamicin vs netilmicin in patients with serious infections. A randomized clinical trial. Clin Otolaryngol 1995; 20:118-23.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились